224 related articles for article (PubMed ID: 11774295)
1. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy.
Lu D; Jimenez X; Zhang H; Bohlen P; Witte L; Zhu Z
Int J Cancer; 2002 Jan; 97(3):393-9. PubMed ID: 11774295
[TBL] [Abstract][Full Text] [Related]
2. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity.
Lu D; Shen J; Vil MD; Zhang H; Jimenez X; Bohlen P; Witte L; Zhu Z
J Biol Chem; 2003 Oct; 278(44):43496-507. PubMed ID: 12917408
[TBL] [Abstract][Full Text] [Related]
3. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.
Zhu Z; Rockwell P; Lu D; Kotanides H; Pytowski B; Hicklin DJ; Bohlen P; Witte L
Cancer Res; 1998 Aug; 58(15):3209-14. PubMed ID: 9699643
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.
Zhu Z; Lu D; Kotanides H; Santiago A; Jimenez X; Simcox T; Hicklin DJ; Bohlen P; Witte L
Cancer Lett; 1999 Mar; 136(2):203-13. PubMed ID: 10355750
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity.
Zhu Z; Hattori K; Zhang H; Jimenez X; Ludwig DL; Dias S; Kussie P; Koo H; Kim HJ; Lu D; Liu M; Tejada R; Friedrich M; Bohlen P; Witte L; Rafii S
Leukemia; 2003 Mar; 17(3):604-11. PubMed ID: 12646950
[TBL] [Abstract][Full Text] [Related]
7. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies.
Lu D; Kussie P; Pytowski B; Persaud K; Bohlen P; Witte L; Zhu Z
J Biol Chem; 2000 May; 275(19):14321-30. PubMed ID: 10799512
[TBL] [Abstract][Full Text] [Related]
8. Anti-VEGFR-2 scFvs for cell isolation. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood.
Böldicke T; Tesar M; Griesel C; Rohde M; Gröne HJ; Waltenberger J; Kollet O; Lapidot T; Yayon A; Weich H
Stem Cells; 2001; 19(1):24-36. PubMed ID: 11209088
[TBL] [Abstract][Full Text] [Related]
9. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.
Binétruy-Tournaire R; Demangel C; Malavaud B; Vassy R; Rouyre S; Kraemer M; Plouët J; Derbin C; Perret G; Mazié JC
EMBO J; 2000 Apr; 19(7):1525-33. PubMed ID: 10747021
[TBL] [Abstract][Full Text] [Related]
10. TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis.
Lee WS; Pyun BJ; Kim SW; Shim SR; Nam JR; Yoo JY; Jin Y; Jin J; Kwon YG; Yun CO; Nam DH; Oh K; Lee DS; Lee SH; Yoo JS
MAbs; 2015; 7(5):957-68. PubMed ID: 25942475
[TBL] [Abstract][Full Text] [Related]
11. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor.
Hetian L; Ping A; Shumei S; Xiaoying L; Luowen H; Jian W; Lin M; Meisheng L; Junshan Y; Chengchao S
J Biol Chem; 2002 Nov; 277(45):43137-42. PubMed ID: 12183450
[TBL] [Abstract][Full Text] [Related]
12. A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library.
El-Mousawi M; Tchistiakova L; Yurchenko L; Pietrzynski G; Moreno M; Stanimirovic D; Ahmad D; Alakhov V
J Biol Chem; 2003 Nov; 278(47):46681-91. PubMed ID: 12954624
[TBL] [Abstract][Full Text] [Related]
13. KDR activation is crucial for VEGF165-mediated Ca2+ mobilization in human umbilical vein endothelial cells.
Cunningham SA; Tran TM; Arrate MP; Bjercke R; Brock TA
Am J Physiol; 1999 Jan; 276(1):C176-81. PubMed ID: 9886933
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy.
Witte L; Hicklin DJ; Zhu Z; Pytowski B; Kotanides H; Rockwell P; Böhlen P
Cancer Metastasis Rev; 1998 Jun; 17(2):155-61. PubMed ID: 9770111
[TBL] [Abstract][Full Text] [Related]
15. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells.
Kanno S; Oda N; Abe M; Terai Y; Ito M; Shitara K; Tabayashi K; Shibuya M; Sato Y
Oncogene; 2000 Apr; 19(17):2138-46. PubMed ID: 10815805
[TBL] [Abstract][Full Text] [Related]
16. Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2.
Lu D; Kotanides H; Jimenez X; Zhou Q; Persaud K; Bohlen P; Witte L; Zhu Z
J Immunol Methods; 1999 Nov; 230(1-2):159-71. PubMed ID: 10594363
[TBL] [Abstract][Full Text] [Related]
17. Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library.
Popkov M; Jendreyko N; Gonzalez-Sapienza G; Mage RG; Rader C; Barbas CF
J Immunol Methods; 2004 May; 288(1-2):149-64. PubMed ID: 15183093
[TBL] [Abstract][Full Text] [Related]
18. Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro.
Benzinger P; Martiny-Baron G; Reusch P; Siemeister G; Kley JT; Marmé D; Unger C; Massing U
Biochim Biophys Acta; 2000 Jun; 1466(1-2):71-8. PubMed ID: 10825432
[TBL] [Abstract][Full Text] [Related]
19. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
Li R; Xiong DS; Shao XF; Liu J; Xu YF; Xu YS; Liu HZ; Zhu ZP; Yang CZ
Acta Pharmacol Sin; 2004 Oct; 25(10):1292-8. PubMed ID: 15456530
[TBL] [Abstract][Full Text] [Related]
20. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex.
Cooke SP; Boxer GM; Lawrence L; Pedley RB; Spencer DI; Begent RH; Chester KA
Cancer Res; 2001 May; 61(9):3653-9. PubMed ID: 11325835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
